<DOC>
	<DOCNO>NCT00625664</DOCNO>
	<brief_summary>This randomize , open-label , multi-center study compare efficacy safety XRP9881 plus cisplatin gemcitabine plus cisplatin first line treatment locally advanced/metastatic urothelial tract bladder cancer . The primary objective compare overall survival . Secondary objective include comparison progression free survival , objective response rate , time definitive deterioration performance status , duration response , time definitive weight loss , assessment overall safety , pharmacokinetics . Patients treated disease progression , death , unacceptable toxicity followed-up death end study whichever come first .</brief_summary>
	<brief_title>Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin First Line Treatment Locally Advanced/Metastatic Urothelial Tract Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Patients histology/cytology confirm Transitional Cell Carcinoma ( TCC ) locally advanced ( T4b ) metastatic urothelial tract bladder cancer ECOG Performance Status 0 1 No prior palliative chemotherapy ( Neo ) Adjuvant chemotherapy &lt; 6 month end ( neo ) adjuvant chemotherapy relapse Less 6 week elapse prior radiotherapy le 3 week surgery time randomization Prior cisplatin ( neo ) adjuvant chemotherapy cumulative dose &gt; 300 mg/mÂ² The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Bladder</keyword>
	<keyword>Urothelial Tract</keyword>
</DOC>